Evaxion A/S (EVAX) Competitors $2.92 -0.02 (-0.68%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$2.88 -0.04 (-1.37%) As of 09/15/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVAX vs. CARM, IXHL, NBY, NRSN, BLRX, ATHA, NERV, CYCC, ETHZ, and COCPShould you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Carisma Therapeutics (CARM), Incannex Healthcare (IXHL), NovaBay Pharmaceuticals (NBY), NeuroSense Therapeutics (NRSN), BioLineRx (BLRX), Athira Pharma (ATHA), Minerva Neurosciences (NERV), Cyclacel Pharmaceuticals (CYCC), Flag Ship Acquisition (ETHZ), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical products" industry. Evaxion A/S vs. Its Competitors Carisma Therapeutics Incannex Healthcare NovaBay Pharmaceuticals NeuroSense Therapeutics BioLineRx Athira Pharma Minerva Neurosciences Cyclacel Pharmaceuticals Flag Ship Acquisition Cocrystal Pharma Evaxion A/S (NASDAQ:EVAX) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation. Which has stronger valuation & earnings, EVAX or CARM? Evaxion A/S has higher earnings, but lower revenue than Carisma Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvaxion A/S$3.34M1.22-$10.57M-$1.32-2.21Carisma Therapeutics$19.63M0.74-$60.48M-$1.56-0.22 Is EVAX or CARM more profitable? Carisma Therapeutics has a net margin of -254.28% compared to Evaxion A/S's net margin of -316.03%. Carisma Therapeutics' return on equity of 0.00% beat Evaxion A/S's return on equity.Company Net Margins Return on Equity Return on Assets Evaxion A/S-316.03% -319.52% -63.56% Carisma Therapeutics -254.28%N/A -192.17% Which has more volatility and risk, EVAX or CARM? Evaxion A/S has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Do analysts rate EVAX or CARM? Evaxion A/S presently has a consensus target price of $10.00, suggesting a potential upside of 242.47%. Carisma Therapeutics has a consensus target price of $1.93, suggesting a potential upside of 456.68%. Given Carisma Therapeutics' higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Evaxion A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71 Do insiders and institutionals hold more shares of EVAX or CARM? 11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer EVAX or CARM? In the previous week, Carisma Therapeutics had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 3 mentions for Carisma Therapeutics and 2 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 1.89 beat Carisma Therapeutics' score of 0.45 indicating that Evaxion A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Carisma Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCarisma Therapeutics beats Evaxion A/S on 9 of the 17 factors compared between the two stocks. Get Evaxion A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVAX vs. The Competition Export to ExcelMetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.13M$2.16B$5.80B$10.17BDividend YieldN/AN/A5.72%4.61%P/E Ratio-2.2135.4275.0526.39Price / Sales1.2210.20544.00190.24Price / CashN/A58.5825.8129.91Price / Book-2.4711.5813.436.28Net Income-$10.57M-$63.67M$3.29B$270.38M7 Day Performance4.29%-1.82%0.08%1.89%1 Month Performance1.39%1.84%4.61%6.01%1 Year Performance-82.03%36.11%75.02%25.26% Evaxion A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVAXEvaxion A/S2.6349 of 5 stars$2.92-0.7%$10.00+242.5%-80.5%$4.13M$3.34M-2.2160News CoveragePositive NewsGap UpCARMCarisma Therapeutics2.6291 of 5 stars$0.38-4.8%$1.93+409.3%-66.1%$15.80M$19.63M-0.2420News CoverageShort Interest ↑IXHLIncannex Healthcare0.1448 of 5 stars$0.54-7.2%N/A-67.5%$15.69M$10K-0.443Short Interest ↑Gap UpNBYNovaBay Pharmaceuticals0.4038 of 5 stars$2.67-1.1%$0.85-68.2%+477.0%$15.55M$9.78M-0.0530Gap UpNRSNNeuroSense Therapeutics2.5748 of 5 stars$1.12-3.4%$14.00+1,150.0%-14.1%$15.38MN/A-2.0810BLRXBioLineRx3.3312 of 5 stars$3.59-1.5%$26.00+625.2%-84.9%$15.28M$28.94M-0.4140Positive NewsATHAAthira Pharma3.0128 of 5 stars$0.38-1.0%$0.50+31.2%-27.3%$15.22MN/A-0.2540NERVMinerva Neurosciences3.7698 of 5 stars$2.16-0.5%$5.00+131.5%-23.7%$15.10MN/A1.469Short Interest ↑CYCCCyclacel Pharmaceuticals0.4103 of 5 stars$6.73-4.5%N/A-97.3%$15.08M$10K-0.0114Short Interest ↑ETHZFlag Ship AcquisitionN/A$2.47+1.2%N/AN/A$14.92MN/A-0.167News CoverageGap UpCOCPCocrystal Pharma2.2617 of 5 stars$1.45-3.3%$6.00+313.8%-14.4%$14.88MN/A-1.1710News CoverageShort Interest ↑Gap Down Related Companies and Tools Related Companies Carisma Therapeutics Competitors Incannex Healthcare Competitors NovaBay Pharmaceuticals Competitors NeuroSense Therapeutics Competitors BioLineRx Competitors Athira Pharma Competitors Minerva Neurosciences Competitors Cyclacel Pharmaceuticals Competitors Flag Ship Acquisition Competitors Cocrystal Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVAX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.